Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Headquartered in Ireland, we also have a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Business segments
Q1 2026 · $415.0MThe company’s own SEC segment disclosure.
- Vivitrol$112.4M27%
- Aristada And Aristada Initio$93.8M23%
- LYBALVI$92.4M22%
- Manufactured Product And Royalty$54.8M13%
- LUMRYZ$39.5M10%
- Royalty$18.0M4%
- Other (1)$4.1M1%
Alkermes plc (ALKS) reported revenue of $393M in Q1 2026 (quarter ended March 31, 2026), up 28% from the same quarter a year earlier. That came with a gross margin of 84% and net loss of $66M. For the full year FY2025, revenue was $1.48B (−5.2% year on year) and net income $242M. Its largest product in 2026-Q1 was Vivitrol at $112M, 27% of the disclosed total, just ahead of Aristada And Aristada Initio at 23%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #21 of 28 by Smart Score